Anavex Life Sciences Corp (AVXL)

[F1ash]

Low Concentration ....MMSE decreases


Low Concentration....
ADCS-ADL decreases

Anyone bother to consider why management would plan the 2b3 trial with the doses that failed the 2a Alzheimer’s trial? Look a pages 23 and 24. https://www.anavex.com/wp-content/uploads/2018/05/Anavex-ANAVEX2-73-CTAD-Phase-2a-November-2017.pdf


The doses on the left are 10 and 20 mgs. There must be a significant reason that they were forced to use those ineffective doses from the 2a trial in the 2b/3 Alzheimer’s and PDD trial.

Look at slide 22. https://www.anavex.com/wp-content/uploads/2018/05/Anavex-ANAVEX2-73-CTAD-Phase-2a-November-2017.pdf

54%
High dose -> Improved response


Low dose -> Improved response
3%

43%
Low dose -> Poor response


Imho only a significant toxicity problem would explain the seemingly inexplicable choice to use 10 and 20 mgs in the current trials.